Listing 13.15 Mesothelioma in 2026

Mesothelioma is a rare but almost always fatal cancer of the thin membranes lining the chest cavity (pleura), abdomen (peritoneum), heart (pericardium), or testis (tunica vaginalis). About 3,000 new cases are diagnosed in the United States each year, with roughly 80% pleural, 15-20% peritoneal, and less than 1% each pericardial or testicular. Median survival for pleural mesothelioma is 12-21 months with modern therapy. Peritoneal mesothelioma treated with cytoreductive surgery plus heated intraperitoneal chemotherapy (HIPEC) can achieve 5-year survival of 40-60%, but most cases are still highly lethal.

SSA Listing 13.15 grants automatic disability upon confirmed diagnosis. There are no staging requirements, no metastasis requirements, no operability tests. If pathology confirms mesothelioma, the listing is met. This walkthrough covers the diagnostic evidence needed, the asbestos exposure history that almost always accompanies the diagnosis, the modern treatment sequence that shapes CDR residuals, and how the 3-year remission rule interacts with the harsh survival numbers.

The listing text

Listing 13.15 covers "Primary sites of malignant neoplastic disease of the pleura, mediastinum, or peritoneum." Mesothelioma at any of these sites qualifies. Any confirmed malignant mesothelioma meets 13.15 regardless of:

• Stage (I, II, III, IV all qualify)
• Histology (epithelioid, sarcomatoid, biphasic all qualify)
• Site (pleural, peritoneal, pericardial, tunica vaginalis all qualify)
• Operability
• Response to treatment

This is one of the most straightforward oncology listings in the Blue Book. The rarity and lethality of mesothelioma justify the automatic qualification. SSA does not require you to prove disease progression, treatment failure, or extent of metastatic spread.

Histologic subtypes and prognosis

Epithelioid mesothelioma (60% of cases)

Most common and best prognosis subtype. Cells resemble normal mesothelial cells. Median survival 12-24 months for pleural, potentially 5+ years for peritoneal with cytoreductive surgery + HIPEC. Better response to systemic therapy and immunotherapy than other subtypes.

Sarcomatoid mesothelioma (10-20% of cases)

Worst prognosis. Cells look like spindle-shaped sarcoma cells. Median survival 6-9 months for pleural. Poor response to conventional chemotherapy. Immunotherapy shows some activity but response rates are lower than epithelioid. Surgery generally not curative for sarcomatoid pleural mesothelioma.

Biphasic (mixed) mesothelioma (20-30% of cases)

Contains both epithelioid and sarcomatoid components. Prognosis intermediate, depending on the proportion of each component. Areas with more than 50% sarcomatoid component behave closer to pure sarcomatoid. Areas with predominant epithelioid component behave closer to pure epithelioid.

Rare variants

Well-differentiated papillary mesothelioma (WDPM) - historically considered indolent, often incidental finding in peritoneum. Now often classified separately from malignant mesothelioma. Deciduoid, lymphohistiocytoid, small-cell, and other rare subtypes exist. Any histologic variant of mesothelioma still meets Listing 13.15.

Diagnostic evidence required

SSA requires objective medical evidence:

• Pathology report from tissue biopsy (CT-guided core biopsy, VATS pleural biopsy, laparoscopic peritoneal biopsy, or surgical specimen) with pathologist's assessment confirming mesothelioma histology
• Immunohistochemistry (IHC) panel distinguishing mesothelioma from carcinoma or other malignancies. Positive mesothelial markers: calretinin, WT1, D2-40 (podoplanin), CK5/6. Negative markers (to rule out adenocarcinoma): CEA, MOC-31, BerEP4, TTF-1, napsin A, claudin-4. Two positive mesothelial markers plus two negative carcinoma markers is standard.
• BAP1 loss and CDKN2A homozygous deletion (by IHC and FISH) - support malignant mesothelioma diagnosis when present, distinguishing from benign mesothelial hyperplasia
• Staging imaging: CT chest/abdomen/pelvis with contrast, PET-CT (FDG) for staging and treatment response, MRI for chest wall or diaphragmatic invasion, brain MRI if symptomatic
• Pulmonary function tests (spirometry with FEV1, FVC, DLCO) - matters for treatment eligibility and 3.02 respiratory residuals
• Asbestos exposure history - documented occupational, environmental, or para-occupational exposure. Not required for SSDI qualification but strongly supports the diagnosis and often documented in the medical record for legal (asbestos trust) claims.

Asbestos exposure history

About 80% of mesothelioma cases are linked to asbestos exposure. Common occupational exposures include:

• Shipyard workers (especially Navy veterans, 30% of US mesothelioma cases)
• Construction workers (insulators, drywall installers, tilers, plumbers)
• Automotive mechanics (brake linings, clutch plates)
• Industrial workers (boilermakers, pipefitters, steelworkers)
• Firefighters
• Power plant workers
• Chemical plant workers

Latency period from exposure to diagnosis is typically 20-50 years. Many patients diagnosed in their 60s-80s had exposure in their 20s-40s.

Para-occupational (secondary) exposure: family members exposed by asbestos brought home on work clothes. This has produced mesothelioma cases in wives and children of asbestos workers.

Environmental exposure: proximity to asbestos mines, ambient exposure in certain geographic areas (Libby, Montana vermiculite; parts of Turkey and Corsica with natural asbestos in soil).

The Compassionate Allowance overlay

Malignant mesothelioma is on the CAL list. All confirmed mesothelioma cases automatically flag for expedited processing, targeting 14-30 days for initial decision. Given the harsh survival statistics, DDS offices process these cases as quickly as possible.

Mesothelioma also frequently qualifies as a Terminal Illness (TERI) case when documented life expectancy is under 6 months.

Modern treatment residuals for the CDR

The 3-year remission rule under 13.00H1 (see our Section 13.00 walkthrough) applies to mesothelioma in theory, but in practice most patients do not reach the 3-year mark. For those who do (particularly peritoneal patients treated with cytoreductive surgery + HIPEC), treatment residuals are extensive.

Cisplatin + pemetrexed chemotherapy

Standard first-line chemotherapy for pleural mesothelioma before immunotherapy became first-line (still used for patients who cannot tolerate immunotherapy or in combination). Residuals include:

• Cisplatin-induced peripheral neuropathy (30-50% at 12+ months)
• Cisplatin-induced ototoxicity (20-40% hearing loss, tinnitus)
• Cisplatin-induced nephrotoxicity (10-20% with permanent GFR reduction)
• Pemetrexed rash, fatigue, mucositis
• Chemotherapy-induced fatigue lasting months to years

Nivolumab + ipilimumab (CheckMate 743)

First-line dual immunotherapy became standard 2020. Particularly effective in sarcomatoid and biphasic histologies. Combined immune-related adverse events higher than single-agent:

• Colitis (10-15% grade 3+) - can require infliximab, prolonged steroids, or permanent discontinuation
• Hepatitis (5-10% grade 3+)
• Pneumonitis (5-8%)
• Hypothyroidism (15-20%, typically permanent)
• Hyperthyroidism transitioning to hypothyroidism
• Adrenal insufficiency (5-10%, permanent)
• Hypophysitis (3-5%, often permanent with panhypopituitarism)
• Type 1 diabetes (1-2%, permanent)
• Neurologic (myasthenia gravis, Guillain-Barre, encephalitis - rare but potentially fatal)
• Cardiac myocarditis (0.5-1%, often fatal)

Endocrine irAEs (hypothyroidism, adrenal insufficiency, hypophysitis, T1DM) are typically lifelong and qualify under 9.00 endocrine listings at CDR.

Tumor treating fields (Optune Lua)

FDA-approved 2019 for unresectable pleural mesothelioma in combination with pemetrexed + platinum. Wearable device delivers alternating electric fields to disrupt tumor mitosis. Skin irritation under transducer arrays common. Requires 18+ hours daily use to be effective.

Cytoreductive surgery + HIPEC (peritoneal)

For peritoneal mesothelioma, complete cytoreductive surgery (CRS) removing all visible disease combined with heated intraperitoneal chemotherapy (HIPEC, typically cisplatin + doxorubicin at 42-43C for 90 minutes) can achieve 5-year survival 40-60% in selected patients. Extensive surgery includes:

• Peritonectomy (removal of visible peritoneum)
• Omentectomy
• Splenectomy (if involved)
• Cholecystectomy (routine to prevent adhesion issues)
• Bowel resections as needed
• Diaphragmatic stripping or resection
• Pelvic peritonectomy
• Hysterectomy + BSO in women

Residuals: bowel adhesions with chronic partial obstruction (30-40%), short bowel syndrome if extensive resection, chronic diarrhea, weight loss, wound complications, hernia, sexual dysfunction, chronic pain. These qualify under 5.00 digestive listings at CDR.

Extended pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP)

P/D removes pleura and any grossly visible tumor while preserving the lung. EPP removes lung, pleura, diaphragm, and pericardium en-bloc. EPP has fallen out of favor due to high morbidity/mortality (5-8% operative mortality) without clear survival benefit vs P/D. Post-surgical residuals:

• Post-EPP: 30-40% FEV1 reduction (loss of entire lung), chronic dyspnea, exercise intolerance - qualifies under 3.02 with PFT thresholds met
• Diaphragm reconstruction with prosthetic mesh can lead to paradoxical breathing
• Pericardial reconstruction with mesh - restrictive pericarditis risk
• Chronic post-thoracotomy pain in 30-50%
• Vocal cord dysfunction from RLN injury

Chest radiation

Radiation for prophylactic (SMART protocol) or palliative purposes. Late effects include radiation pneumonitis, chronic fibrosis, cardiac toxicity if left-sided, esophageal strictures.

Worked case examples

Case 1: Frank, 76, New Jersey, epithelioid pleural mesothelioma, Navy shipyard veteran

Frank served in the US Navy 1968-1972 as a machinist mate on destroyers with extensive asbestos insulation. Post-service worked as an industrial pipefitter for 35 years. In January 2026 developed progressive shortness of breath and right-sided chest pain. CXR showed right pleural effusion. CT chest showed nodular pleural thickening and 1.8 L pleural effusion. Thoracentesis: exudate with atypical cells. VATS pleural biopsy: epithelioid mesothelioma with calretinin+ WT1+ D2-40+ CK5/6+ and negative CEA/TTF-1/MOC-31. Stage III (T3N1M0).

SSDI application filed February 2026. CAL for mesothelioma triggered automatic expedited processing. Approved 11 days at New Jersey DDS. Started nivolumab + ipilimumab per CheckMate 743. Also filed VA claim for service-connected asbestos exposure (mesothelioma is presumed service-connected for Navy veterans exposed to asbestos) and asbestos trust claims. Died December 2026, 11 months post-diagnosis.

Case 2: Angela, 62, Texas, peritoneal mesothelioma with HIPEC

Angela presented with 3 months of abdominal distension and 20 lb weight loss in March 2026. CT abdomen showed peritoneal thickening, omental caking, and 4 L ascites. Paracentesis: exudate with atypical cells. Laparoscopy with biopsy: epithelioid peritoneal mesothelioma. Peritoneal Cancer Index (PCI) 24 out of 39.

SSDI application filed April 2026. CAL for mesothelioma triggered. Approved 14 days at Texas DDS. Referred to peritoneal surface malignancy center. Received 4 cycles neoadjuvant cisplatin + pemetrexed, then complete cytoreductive surgery (peritonectomy + omentectomy + splenectomy + cholecystectomy + right hemicolectomy + hysterectomy + BSO + diaphragmatic stripping) with HIPEC cisplatin 100 mg/m2 at 42.5C for 90 minutes. No residual disease. Adjuvant nivolumab. Ongoing at 6-month follow-up. Chronic short bowel syndrome from right hemicolectomy + extensive small bowel adhesion release now qualifies under 5.08 short bowel at future CDR.

Case 3: Robert, 68, Pennsylvania, sarcomatoid pleural mesothelioma

Robert worked as an insulator for 30 years. Presented in May 2026 with left chest wall pain and 15 lb weight loss. CT showed diffuse left pleural thickening with chest wall invasion at ribs 5-7. CT-guided biopsy: sarcomatoid mesothelioma. Stage IIIB (T3N0M0, considered unresectable given chest wall invasion and sarcomatoid histology).

SSDI application filed May 2026. Approved 12 days at Pennsylvania DDS. Started nivolumab + ipilimumab (particularly effective in sarcomatoid per CheckMate 743). Partial response at 3 months. Also filed asbestos trust claims and personal injury litigation against former employer insulation product manufacturers.

What to file with your application

1. Pathology report with mesothelioma histologic subtype and IHC panel
2. Staging imaging: CT chest/abdomen/pelvis, PET-CT, MRI as applicable
3. Oncology consultation notes with stage assignment and treatment plan
4. Pulmonary function tests
5. Occupational history documenting asbestos exposure (helpful for VA claims and asbestos trusts even if not required for SSDI)
6. Military service records if applicable (Navy veterans have presumed service connection)
7. Any hospitalization records for treatment complications

Other benefits to pursue in parallel

Mesothelioma patients typically pursue multiple parallel benefit tracks alongside SSDI:

• VA disability for veterans with service-connected asbestos exposure. Mesothelioma is presumed service-connected for Navy veterans and certain other MOS with asbestos exposure. Rating typically 100%.
• Asbestos trust fund claims - about 60 asbestos trust funds hold combined assets of $30+ billion for mesothelioma victims. Claims processed based on exposure history and diagnosis, typically $50k-$500k+ per trust, filed through specialized attorneys.
• Personal injury litigation against solvent asbestos product manufacturers. Settlements or verdicts commonly range from $1M to $10M+ for mesothelioma cases.
• Workers compensation in states with occupational disease coverage.

Related reading

Full section walkthrough: Section 13.00 cancer basics. Companion lung cancer piece: 13.14 lung cancer. Related respiratory listing: 3.11 lung transplantation. Companion skin cancer piece: 13.12 melanoma.

Frequently asked questions

Next steps

If you were diagnosed with mesothelioma, file for SSDI immediately after pathology confirmation. Simultaneously pursue VA disability if you are a veteran, asbestos trust fund claims, and consult a mesothelioma attorney about personal injury litigation.